keyword
MENU ▼
Read by QxMD icon Read
search

Cognitive impairment associated with schizophrenia

keyword
https://www.readbyqxmd.com/read/29768190/a-bayesian-model-comparison-approach-to-test-the-specificity-of-visual-integration-impairment-in-schizophrenia-or-psychosis
#1
Tyler B Grove, Beier Yao, Savanna A Mueller, Merranda McLaughlin, Vicki L Ellingrod, Melvin G McInnis, Stephan F Taylor, Patricia J Deldin, Ivy F Tso
Impaired visual integration is well documented in schizophrenia and related to functional outcomes. However, it is unclear if this deficit is specific to schizophrenia, or characteristic of psychosis more broadly. To address this question, this study used a Bayesian model comparison approach to examine the evidence of three grouping models of visual integration performance in 116 individuals with schizophrenia (SZ), schizoaffective disorder (SA), bipolar disorder (BD) with or without a history of prominent psychosis (BDP+ and BDP-, respectively), or no psychiatric diagnosis (healthy controls; HC)...
May 7, 2018: Psychiatry Research
https://www.readbyqxmd.com/read/29765027/polygenic-pleiotropy-and-potential-causal-relationships-between-educational-attainment-neurobiological-profile-and-positive-psychotic-symptoms
#2
Yen-Feng Lin, Chia-Yen Chen, Dost Öngür, Rebecca Betensky, Jordan W Smoller, Deborah Blacker, Mei-Hua Hall
Event-related potential (ERP) components have been used to assess cognitive functions in patients with psychotic illness. Evidence suggests that among patients with psychosis there is a distinct heritable neurophysiologic phenotypic subtype captured by impairments across a range of ERP measures. In this study, we investigated the genetic basis of this "globally impaired" ERP cluster and its relationship to psychosis and cognitive abilities. We applied K-means clustering to six ERP measures to re-derive the globally impaired (n = 60) and the non-globally impaired ERP clusters (n = 323) in a sample of cases with schizophrenia (SCZ = 136) or bipolar disorder (BPD = 121) and healthy controls (n = 126)...
May 16, 2018: Translational Psychiatry
https://www.readbyqxmd.com/read/29764760/altered-predictive-capability-of-the-brain-network-eeg-model-in-schizophrenia-during-cognition
#3
Javier Gomez-Pilar, Jesús Poza, Carlos Gómez, Georg Northoff, Alba Lubeiro, Benjamín B Cea-Cañas, Vicente Molina, Roberto Hornero
The study of the mechanisms involved in cognition is of paramount importance for the understanding of the neurobiological substrates in psychiatric disorders. Hence, this research is aimed at exploring the brain network dynamics during a cognitive task. Specifically, we analyze the predictive capability of the pre-stimulus theta activity to ascertain the functional brain dynamics during cognition in both healthy and schizophrenia subjects. Firstly, EEG recordings were acquired during a three-tone oddball task from fifty-one healthy subjects and thirty-five schizophrenia patients...
May 12, 2018: Schizophrenia Research
https://www.readbyqxmd.com/read/29763637/neurosteroid-pregnenolone-sulfate-alone-and-as-augmentation-of-lurasidone-or-tandospirone-rescues-phencyclidine-induced-deficits-in-cognitive-function-and-social-interaction
#4
L Rajagopal, D Soni, H Y Meltzer
BACKGROUND: Pregnenolone sulfate (PregS), an endogenous neurosteroid, which negatively and positively modulates gamma amino butyric acid subunit A (GABAA ) and N-methyl D-aspartate (NMDA) receptors (R) respectively, among other potential neuroplastic changes on synaptic processes, has shown some beneficial effects on treating cognitive impairment associated with schizophrenia (CIAS) and negative symptoms. Lurasidone (Lur), an atypical antipsychotic drug (AAPD), and tandospirone (Tan), a 5-HT1A  R partial agonist, have also been reported to improve cognitive or negative symptoms, or both, in some schizophrenia patients...
May 12, 2018: Behavioural Brain Research
https://www.readbyqxmd.com/read/29752710/inflammation-in-psychiatric-disorders-what-comes-first
#5
REVIEW
Moisés E Bauer, Antonio L Teixeira
Neuropsychiatric disorders (i.e., mood disorders and schizophrenia) and inflammation are closely intertwined, and possibly powering each other in a bidirectional loop. Depression facilitates inflammatory reactions and inflammation promotes depression and other neuropsychiatric disorders. Patients with neuropsychiatric disorders exhibit all cardinal features of inflammation, including increased circulating levels of inflammatory inducers, activated sensors, and inflammatory mediators targeting all tissues. Inflammation may contribute to the pathophysiology and clinical progression of these disorders...
May 11, 2018: Annals of the New York Academy of Sciences
https://www.readbyqxmd.com/read/29747665/comprehensive-behavioral-analysis-of-mice-deficient-in-rapgef2-and-rapgef6-a-subfamily-of-guanine-nucleotide-exchange-factors-for-rap-small-gtpases-possessing-the-ras-rap-associating-domain
#6
Kazuhiro Maeta, Satoko Hattori, Junji Ikutomo, Hironori Edamatsu, Shymaa E Bilasy, Tsuyoshi Miyakawa, Tohru Kataoka
Rapgef2 and Rapgef6 define a subfamily of guanine nucleotide exchange factors for Rap small GTPases, characterized by the possession of the Ras/Rap-associating domain. Previous genomic analyses suggested their possible involvement in the etiology of schizophrenia. We recently demonstrated the development of an ectopic cortical mass (ECM), which resembles the human subcortical band heterotopia, in the dorsal telencephalon-specific Rapgef2 conditional knockout (Rapgef2-cKO) brains. Additional knockout of Rapgef6 in Rapgef2-cKO mice resulted in gross enlargement of the ECM whereas knockout of Rapgef6 alone (Rapgef6-KO) had no discernible effect on the brain morphology...
May 10, 2018: Molecular Brain
https://www.readbyqxmd.com/read/29742910/an-overview-of-animal-models-related-to-schizophrenia
#7
Ian R Winship, Serdar M Dursun, Glen B Baker, Priscila A Balista, Ludmyla Kandratavicius, Joao Paulo Maia-de-Oliveira, Jaime Hallak, John G Howland
Schizophrenia is a heterogeneous psychiatric disorder that is poorly treated with current therapies. In this brief review, we provide an update regarding the use of animal models to study schizophrenia in an attempt to understand its aetiology and develop novel therapeutic strategies. Tremendous progress has been made developing and validating rodent models that replicate the aetiologies, brain pathologies, and behavioural abnormalities associated with schizophrenia in humans. Here, models are grouped into 3 categories-developmental, drug induced, and genetic-to reflect the heterogeneous risk factors associated with schizophrenia...
January 1, 2018: Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie
https://www.readbyqxmd.com/read/29740360/the-importance-of-social-cognition-in-improving-functional-outcomes-in-schizophrenia
#8
REVIEW
Afzal Javed, Asha Charles
Social cognition has become recognized as an important driver of functional outcomes and overall recovery in patients with schizophrenia, mediating the relationship between neurocognition and social functioning. Since antipsychotic therapy targeting remission of clinical symptoms has been shown to have a limited impact on social cognition, there has been an increasing drive to develop therapeutic strategies to specifically improve social cognition in schizophrenia. We sought to review current evidence relating to social cognition in schizophrenia and its clinical implications, including interventions designed to target the core domains of social cognition (emotion processing, theory of mind, attributional bias, and social perception) as a means of improving functional outcomes and thereby increasing the likelihood of recovery...
2018: Frontiers in Psychiatry
https://www.readbyqxmd.com/read/29735555/genetic-activation-inactivation-and-deletion-reveal-a-limited-and-nuanced-role-for-somatostatin-containing-basal-forebrain-neurons-in-behavioral-state-control
#9
Christelle Anaclet, Roberto De Luca, Anne Venner, Olga Malyshevskaya, Michael Lazarus, Elda Arrigoni, Patrick M Fuller
Recent studies have identified an especially important role for basal forebrain GABAergic (BFVGAT ) neurons in the regulation of behavioral waking and fast cortical rhythms associated with cognition. However, BFVGAT neurons comprise several neurochemically and anatomically distinct sub-populations, including parvalbumin- and somatostatin-containing BFVGAT neurons (BFParv and BFSOM ), and it was recently reported that optogenetic activation of BFSOM neurons increases the probability of a wakefulness to non-rapid-eye movement (NREM) sleep transition when stimulated during the animal's rest period...
May 7, 2018: Journal of Neuroscience: the Official Journal of the Society for Neuroscience
https://www.readbyqxmd.com/read/29730044/association-between-catechol-o-methyltransferase-genetic-variation-and-functional-connectivity-in-patients-with-first-episode-schizophrenia
#10
Hongyan Wang, Bin Zhang, Botao Zeng, Yingying Tang, Tianhong Zhang, Shanshan Zhao, Chunbo Li, Jijun Wang, Donald C Goff
Dopamine in the prefrontal cortex (PFC) plays an important role in cognitive performance and regulates by catechol-O-methyltransferase (COMT) expression. To clarify the effect of COMT genotype on cognitive function in patients with schizophrenia, we performed DNA genotyping, cognitive evaluations, and functional magnetic resonance imaging (fMRI) in antipsychotic-naïve patients with first-episode schizophrenia (FES) and matched healthy control subjects. We found that all cognitive domains were impaired in patients with FES compared with healthy subjects...
May 3, 2018: Schizophrenia Research
https://www.readbyqxmd.com/read/29718385/evaluation-of-the-efficacy-safety-and-tolerability-of-bi-409306-a-novel-phosphodiesterase-9-inhibitor-in-cognitive-impairment-in-schizophrenia-a-randomized-double-blind-placebo-controlled-phase-ii-trial
#11
David Brown, Kazuyuki Nakagome, Joachim Cordes, Ronald Brenner, Gerhard Gründer, Richard S E Keefe, Robert Riesenberg, David P Walling, Kristen Daniels, Lara Wang, Jennifer McGinniss, Michael Sand
Background: Patients with cognitive impairment associated with schizophrenia may benefit from treatments targeting dysfunctional glutamatergic neurotransmission. BI 409306, a potent and selective phosphodiesterase 9 inhibitor, was assessed in patients with schizophrenia using a learn-and-confirm adaptive trial design. Methods: This double-blind, parallel-group trial randomized patients 2:1:1:1:1 to once-daily placebo or BI 409306 (10, 25, 50, or 100 mg) for 12 weeks...
May 1, 2018: Schizophrenia Bulletin
https://www.readbyqxmd.com/read/29717334/the-role-of-striatal-dopamine-d-2-3-receptors-in-cognitive-performance-in-drug-free-patients-with-schizophrenia
#12
Tanja Veselinović, Ingo Vernaleken, Hildegard Janouschek, Paul Cumming, Michael Paulzen, Felix M Mottaghy, Gerhard Gründer
OBJECTIVE: A considerable body of research links cognitive function to dopaminergic transmission in the prefrontal cortex, but less is known about cognition in relation to striatal dopamine D2/3 receptors in unmedicated patients with psychosis. METHODS: We investigated this association by obtaining PET recordings with the high-affinity D2/3 antagonist ligand [18 F] fallypride in 15 medication-free patients with schizophrenia and 11 healthy controls. On the day of PET scanning, we undertook comprehensive neuropsychological testing and assessment of psychopathology using the Positive and Negative Syndrome Scale (PANSS)...
May 1, 2018: Psychopharmacology
https://www.readbyqxmd.com/read/29713787/cognitive-profile-of-ketamine-dependent-patients-compared-with-methamphetamine-dependent-patients-and-healthy-controls
#13
Liang-Jen Wang, Chih-Ken Chen, Shih-Ku Lin, Yi-Chih Chen, Ke Xu, Ming-Chyi Huang
BACKGROUND: Ketamine has emerged as a major substance of abuse worldwide and has been listed with methamphetamine (METH) as two of the most widely available illicit substances in Taiwan. Only a few studies have examined the long-term consequences of chronic and heavy ketamine abuse. We compared the cognitive function of ketamine-dependent patients with that of METH-dependent patients and healthy controls. METHODS: We recruited 165 participants (58 ketamine-dependent and 49 METH-dependent patients who sought treatment and 58 healthy controls) and evaluated them by using a cognitive test battery, the Brief Assessment of Cognition in Schizophrenia, with scores being estimated in reference to normative data in general population...
April 30, 2018: Psychopharmacology
https://www.readbyqxmd.com/read/29709790/associations-between-cognition-and-internalizing-problems-in-young-adults-with-early-onset-schizophrenia-a-13-year-follow-up-study
#14
Benedicte Strugstad, Bjørn Lau, Merete Glenne Øie
The present follow-up study examines the associations between cognition and parent-rated internalizing problems among adolescents with early-onset schizophrenia (EOS) at baseline (T1) and self-rated internalizing problems 13 years later (T2). Twelve individuals (8 male/4 female) with EOS and 30 healthy controls (16 male/14 female) were included in the study. All were between 12 and 18 years of age at T1. Internalizing problems were measured with the Achenbach System of Empirically Based Assessment Internalizing Scale...
April 12, 2018: Psychiatry Research
https://www.readbyqxmd.com/read/29692285/metacognitive-reflection-and-insight-therapy-merit-for-patients-with-schizophrenia
#15
S de Jong, R J M van Donkersgoed, M E Timmerman, M Aan Het Rot, L Wunderink, J Arends, M van Der Gaag, A Aleman, P H Lysaker, G H M Pijnenborg
BACKGROUND: Impaired metacognition is associated with difficulties in the daily functioning of people with psychosis. Metacognition can be divided into four domains: Self-Reflection, Understanding the Other's Mind, Decentration, and Mastery. This study investigated whether Metacognitive Reflection and Insight Therapy (MERIT) can be used to improve metacognition. METHODS: This study is a randomized controlled trial. Patients in the active condition (n = 35) received forty MERIT sessions, the control group (n = 35) received treatment as usual...
April 25, 2018: Psychological Medicine
https://www.readbyqxmd.com/read/29673732/self-assessment-of-social-cognitive-ability-in-schizophrenia-association-with-social-cognitive-test-performance-informant-assessments-of-social-cognitive-ability-and-everyday-outcomes
#16
Juliet M Silberstein, Amy E Pinkham, David L Penn, Philip D Harvey
BACKGROUND: Impairments in self-assessment are common in people with schizophrenia and impairments in self-assessment of cognitive ability have been found to predict impaired functional outcome. In this study, we examined self-assessment of social cognitive ability and related them to assessments of social cognition provided by informants, to performance on tests of social cognition, and to everyday outcomes. The difference between self-reported social cognition and informant ratings was used to predict everyday functioning...
April 17, 2018: Schizophrenia Research
https://www.readbyqxmd.com/read/29667043/abnormalities-in-thalamo-cortical-connections-in-patients-with-first-episode-schizophrenia-a-two-tensor-tractography-study
#17
Hesham M Hamoda, A T Makhlouf, J Fitzsimmons, Y Rathi, N Makris, R I Mesholam-Gately, J D Wojcik, J Goldstein, R W McCarley, L J Seidman, M Kubicki, M E Shenton
The "cognitive dysmetria" hypothesis suggests that impairments in cognition and behavior in patients with schizophrenia can be explained by disruptions in the cortico-cerebellar-thalamic-cortical circuit. In this study we examine thalamo-cortical connections in patients with first-episode schizophrenia (FESZ). White matter pathways are investigated that connect the thalamus with three frontal cortex regions including the anterior cingulate cortex (ACC), ventrolateral prefrontal cortex (VLPFC), and lateral oribitofrontal cortex (LOFC)...
April 17, 2018: Brain Imaging and Behavior
https://www.readbyqxmd.com/read/29643356/disc1-regulates-lactate-metabolism-in-astrocytes-implications-for-psychiatric-disorders
#18
Yan Jouroukhin, Yusuke Kageyama, Varvara Misheneva, Alexey Shevelkin, Shaida Andrabi, Emese Prandovszky, Robert H Yolken, Valina L Dawson, Ted M Dawson, Susan Aja, Hiromi Sesaki, Mikhail V Pletnikov
Our knowledge of how genetic risk variants contribute to psychiatric disease is mainly limited to neurons. However, the mechanisms whereby the same genetic risk factors could affect the physiology of glial cells remain poorly understood. We studied the role of a psychiatric genetic risk factor, Disrupted-In-Schizophrenia-1 (DISC1), in metabolic functions of astrocytes. We evaluated the effects of knockdown of mouse endogenous DISC1 (DISC1-KD) and expression of a dominant-negative, C-terminus truncated human DISC1 (DN-DISC1) on the markers of energy metabolism, including glucose uptake and lactate production, in primary astrocytes and in mice with selective expression of DN-DISC1 in astrocytes...
April 12, 2018: Translational Psychiatry
https://www.readbyqxmd.com/read/29620518/examining-cognition-across-the-bipolar-schizophrenia-diagnostic-spectrum
#19
Amy J Lynham, Leon Hubbard, Katherine E Tansey, Marian L Hamshere, Sophie E Legge, Michael J Owen, Ian R Jones, James T R Walters
BACKGROUND: Cognitive impairments are well-established features of schizophrenia, but there is ongoing debate about the nature and degree of cognitive impairment in patients with schizoaffective disorder and bipolar disorder. We hypothesized that there is a spectrum of increasing impairment from bipolar disorder to schizoaffective disorder bipolar type, to schizoaffective disorder depressive type and schizophrenia. METHODS: We compared performance on the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery between participants with schizophrenia ( n = 558), schizoaffective disorder depressive type ( n = 112), schizoaffective disorder type ( n = 76), bipolar disorder ( n = 78) and healthy participants ( n = 103) using analysis of covariance with post hoc comparisons...
April 5, 2018: Journal of Psychiatry & Neuroscience: JPN
https://www.readbyqxmd.com/read/29619533/the-effects-of-cannabidiol-cbd-on-cognition-and-symptoms-in-outpatients-with-chronic-schizophrenia-a-randomized-placebo-controlled-trial
#20
Douglas L Boggs, Toral Surti, Aarti Gupta, Swapnil Gupta, Mark Niciu, Brian Pittman, Ashley M Schnakenberg Martin, Halle Thurnauer, Andrew Davies, Deepak C D'Souza, Mohini Ranganathan
RATIONALE: Preliminary evidence suggests that cannabidiol (CBD) may be effective in the treatment of neurodegenerative disorders; however, CBD has never been evaluated for the treatment of cognitive impairments associated with schizophrenia (CIAS). OBJECTIVE: This study compared the cognitive, symptomatic, and side effects of CBD versus placebo in a clinical trial. METHODS: This study was a 6-week, randomized, placebo-controlled, parallel group, fixed-dose study of oral CBD (600 mg/day) or placebo augmentation in 36 stable antipsychotic-treated patients diagnosed with chronic schizophrenia...
April 5, 2018: Psychopharmacology
keyword
keyword
66613
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"